Genomic Regulation and Translational Potential of a Novel Smooth Muscle Cell-Derived Cell Type in Atherosclerosis

动脉粥样硬化中新型平滑肌细胞衍生细胞类型的基因组调控和转化潜力

基本信息

  • 批准号:
    10553197
  • 负责人:
  • 金额:
    $ 16.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-20 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

Smooth muscle cells (SMCs) play major roles in atherosclerosis, a leading cause of cardiovascular disease (CVD). SMCs can be beneficial or detrimental in atherosclerosis, depending on their transdifferentiation trajectories into atheroprotective (e.g., fibroblast-like cell) or atherogenic (e.g., macrophage) cell types. My recent work, combining an SMC-lineage tracing murine model and single-cell RNA sequencing (scRNA-seq), revealed a novel SMC-derived cell type, “SEM” cell (termed because of co-expression of stem cell, endothelial cell, and monocyte markers). SMC-derived SEM-like cells have also been identified by other groups. SEM cells highly express genes related to proatherogenic functions (e.g., inflammation) and may be the precursors for other SMC- derived cell types (e.g., fibrochondrocyte, macrophage), through which SEM cells may modulate vulnerability and stability of atherosclerotic lesions. My proof of principle studies in mouse models showed that activation of retinoic acid (RA) signaling inhibited SMC to SEM cell transition, reduced atherosclerotic burden, and promoted fibrous cap stability in atherosclerosis. These findings suggest the following central hypotheses: 1) activation of RA signaling attenuates SMC to SEM cell transition by directly suppressing expression of key SEM cell marker genes; 2) activation of RA signaling represses proatherogenic functions (e.g., inflammation) of SEM cells during disease progression; 3) activation of RA signaling is beneficial in established atherosclerosis and accelerates disease regression by promoting SEM cell atheroprotective functions and differentiation trajectories while suppressing atheroprone features of SEM cells. These hypotheses will be addressed through the following aims: Aim 1 (K99 phase) will determine if RA signaling inhibits the SMC to SEM cell transition via RAR/RXR/EZH2- mediated repression of SEM cell marker genes; Aim 2 (K99 phase) will determine if RA signaling attenuates SEM cell inflammation during atherosclerosis progression through LXR-mediated repression of inflammatory genes; Aim 3 (R00 phase) will apply SMC-lineage tracing and atherosclerosis regression mouse models to determine if RA signaling drives differentiation trajectories of SEM cells towards atheroprotective rather than atherogenic cell types in advanced atherosclerosis (Aim 3A) and promotes SEM cell apoptosis and subsequent resorption via macrophage efferocytosis during disease regression (Aim 3B). The proposed studies will be accomplished in the setting of a comprehensive career development program designed to provide the candidate with scientific and leadership skills that facilitate the successful transition to an independent investigator in the field of atherosclerotic CVD. At the K99 phase, the candidate will continue to obtain expertise in molecular, cellular, and biochemical techniques as well as SMC-lineage tracing and mechanistic and functional investigation of RA signaling and SEM cells in atherosclerosis mouse models for progressing, advanced, and regressing lesions. The expert advisory team will guide the candidate in research training, manuscript and grant proposal preparation, and ultimately in the transition to an independence career over the course of the award period.
血管平滑肌细胞(SMC)在动脉粥样硬化中起主要作用,动脉粥样硬化是心血管疾病的主要原因 (CVD)。平滑肌细胞在动脉粥样硬化中可能是有益的,也可能是有害的,这取决于它们的转分化。 进入动脉粥样硬化保护性(如成纤维细胞样细胞)或致动脉粥样硬化(如巨噬细胞)细胞类型的轨迹。我最近的经历 结合SMC谱系追踪小鼠模型和单细胞RNA测序(scRNA-seq)的工作揭示 一种新的SMC来源的细胞类型,“SEM”细胞(因干细胞、内皮细胞和 单核细胞标志物)。SMC来源的扫描电子显微镜样细胞也被其他研究小组鉴定。扫描电子显微镜细胞高度 表达与促动脉粥样硬化功能(如炎症)相关的基因,并可能是其他SMC- 衍生细胞类型(如纤维软骨细胞、巨噬细胞),扫描电子显微镜细胞可通过这些细胞类型调节脆弱性 和动脉粥样硬化病变的稳定性。我在小鼠模型中的原理研究证明,激活 维甲酸(RA)信号转导抑制SMC向SMC的转化,减轻动脉粥样硬化负荷,促进 动脉粥样硬化中纤维帽的稳定性。这些发现提出了以下中心假设:1)激活 RA信号通过直接抑制关键的扫描电子显微镜细胞标志物的表达来减弱SMC向扫描电子显微镜细胞的转化 基因;2)RA信号的激活抑制了SEM细胞的促动脉粥样硬化功能(如炎症) 疾病进展;3)RA信号的激活在已建立的动脉粥样硬化中有益并加速 促进扫描电子显微镜细胞动脉粥样硬化保护功能和分化轨迹的疾病逆转 抑制扫描电子显微镜细胞的动脉粥样硬化特征。这些假设将通过以下目标加以解决: AIM 1(K99期)将决定RA信号是否通过RAR/RXR/EZH2-抑制SMC向SEM细胞的转化。 介导对扫描电子显微镜细胞标记基因的抑制;Aim 2(K99期)将决定RA信号是否减弱 扫描电子显微镜观察LXR介导的炎症抑制在动脉粥样硬化进展中的细胞炎症 基因;Aim 3(R00阶段)将应用SMC谱系追踪和动脉粥样硬化回归小鼠模型 确定RA信号是否推动SEM细胞向动脉粥样硬化保护方向分化,而不是 晚期动脉粥样硬化的致动脉粥样硬化细胞类型(AIM 3A)并促进扫描电子显微镜细胞凋亡和随后的 疾病消退期间通过巨噬细胞泡出的吸收(目标3B)。拟议的研究将是 在全面职业发展计划的背景下完成,旨在为应聘者提供 具有科学和领导技能,有助于成功过渡到独立调查员 动脉粥样硬化性心血管疾病领域。在K99阶段,候选人将继续获得分子、 细胞和生化技术以及SMC谱系追踪和机制和功能研究 RA信号和扫描电子显微镜细胞在动脉粥样硬化小鼠模型进展、进展和消退中的作用 损伤。专家咨询组将指导候选人进行研究培训、稿件和拨款提案 在整个颁奖过程中,他一直在做准备工作,并最终过渡到独立的职业生涯。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Huize Pan其他文献

Huize Pan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Huize Pan', 18)}}的其他基金

Genomic Regulation and Translational Potential of a Novel Smooth Muscle Cell-Derived Cell Type in Atherosclerosis
动脉粥样硬化中新型平滑肌细胞衍生细胞类型的基因组调控和转化潜力
  • 批准号:
    10371660
  • 财政年份:
    2022
  • 资助金额:
    $ 16.55万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了